Novo Nordisk's pricing tactics during the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of rate gouging, pointing out the stark contrast involving U.S. costs and those in Europe and copyright. Knowledge the output prices is important for